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ABSTRACT: Background: PD diagnosis is based pri-
marily on clinical criteria and can be inaccurate. Biological
markers, such as α-synuclein aggregation, that reﬂect ongo-
ing pathogenic processes may increase diagnosis accu-
racy and allow disease progression monitoring. Though
α-synuclein aggregation assays have been published,
reproducibility, standardization, and validation are key
challenges for their development as clinical biomarkers.
Objective: To cross-validate two α-synuclein seeding
aggregation assays developed to detect pathogenic oligo-
meric α-synuclein species in CSF using samples from the
same PD patients and healthy controls from the BioFIND
cohort.
Methods: CSF samples were tested by two independent
laboratories in a blinded fashion. BioFIND features standard-
ized biospecimen collection of clinically typical moderate PD
patients and nondisease controls. α-synuclein aggregation
was measured by protein misfolding cyclic ampliﬁcation
(Soto lab) and real-time quaking-induced conversion (Green
lab). Results were analyzed by an independent statistician.
Results: Measuring 105 PD and 79 healthy control CSF
samples, these assays showed 92% concordance. The
areas under the curve from receiver operating characteristic
curve analysis for the diagnosis of PD versus healthy controls
were 0.93 for protein misfolding cyclic ampliﬁcation, 0.89 for
real-time quaking-induced conversion, and 0.95 when con-
sidering only concordant assay results. Clinical characteris-
tics of false-positive and -negative subjects were not different
from true-negative and -positive subjects, respectively.
Conclusions: These α-synuclein seeding aggregation
assays are reliable and reproducible for PD diagnosis.
Assay parameters did not correlate with clinical parame-
ters, including disease severity or duration. This assay is
highly accurate for PD diagnosis and may impact clinical
practice and clinical trials. © 2019 The Authors. Movement
Disorders published by Wiley Periodicals, Inc. on behalf of
International Parkinson and Movement Disorder Society.
Key Words: Parkinson’s disease; α-synuclein; aggrega-
tion; biomarker
Parkinson’s disease (PD) diagnosis relies primarily
on clinical identiﬁcation of cardinal motor symptoms
(bradykinesia, rigidity, and resting tremor). However,
clinical manifestation of PD is heterogeneous and over-
laps with other related neurodegenerative disorders,
which can hinder accurate diagnosis.1-5 Although many
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
This is an open access article under the terms of the Creative
Commons Attribution License, which permits use, distribution and
reproduction in any medium, provided the original work is properly
cited.
*Correspondence to: Dr. Un Jung Kang, Department of Neurology,
Columbia University Medical Center, 710 West 168th Street, New York,
NY 10032, USA; E-mail: ujk2101@columbia.edu
U.J.K., A.G., and C.S. contributed equally to the manuscript.
Funding agencies: These studies are funded by the Michael
J. Fox Foundation for Parkinson’s Research and the NIH-NINDS.
Relevant conﬂicts of interest/ﬁnancial disclosures: Dr. Kang,
Dr. Boehme and Dr. Ma report no conﬂicts of interest relevant to
this work. Dr. Green and Mr. Fairfoul have a patent (PCT/GB2017/
0519 88; α-synuclein detection assay) pending and a patent null
pending. Dr. Soto and Dr. Shahnawaz has a patent (Detection of
misfolded alpha synuclein protein) pending. Dr. Soto is the founder,
Chief Scientiﬁc Ofﬁcer, and major shareholder of Amprion Inc., a
biotech company aiming to commercialize the use of seeding
aggregation assays, including PMCA and RT-QuIC, for the diagno-
sis of neurodegenerative disease. Dr. Hutten is employed by the
Michael J. Fox Foundation.
Full ﬁnancial disclosures and author roles may be found in the
online version of this article.
Received: 18 November 2018; Revised: 18 January 2019; Accepted:
28 January 2019
Published online 00 Month 2019 in Wiley Online Library
(wileyonlinelibrary.com). DOI: 10.1002/mds.27646
Movement Disorders, 2019 1
studies have reported biochemical differences in bioﬂuids
from PD and healthy control (HC) patients, these differ-
ences are often at the population level, with signiﬁcant
overlap between groups, and are not useful diagnostic
tests for individual patients.6 Currently, dopaminergic
imaging methods provide the highest accuracy for diag-
nosing parkinsonism, although they neither distinguish
PD from parkinsonism with dopaminergic deﬁcit nor
report on the pathogenesis of decreased dopamine
levels.7 Therefore, reliable biomarkers for common fea-
tures and pathogenic processes will increase the accuracy
of diagnosis, and facilitate clinical care and therapeutic
development.
α-Synuclein dysfunction plays a prominent role in PD
pathogenesis. Aggregated α-synuclein protein is a major
constituent of Lewy bodies, and mutations in the SNCA
gene encoding α-synuclein cause genetic forms of PD.8-10
α-Synuclein protein exists in monomeric and oligomeric
forms; in PD, α-synuclein oligomers adopt conformations
that promote aggregation and are thought to confer
pathogenicity.11,12 These “pathologic” oligomers can
act as prions to propagate their conformation to native
α-synuclein.12 Recent studies reported that cerebrospi-
nal ﬂuid (CSF) from PD patients can seed aggregation
of recombinant α-synuclein in vitro, which showed a high
degree of concordance with PD diagnosis.13-15 However,
the lack of cross-validation of potential biomarkers is a
major challenge in the ﬁeld to ensure assay validity and
reproducibility for further development.16 Therefore, we
undertook a blinded study of two similar assays that were
separately developed by independent laboratories. These
two platforms tested CSF from the same subjects in the
BioFIND cohort, which utilized standardized biospecimen
collection protocols of clinically typical and well-deﬁned
moderate PD patients and healthy controls.17,18
Materials and Methods
BioFIND study and design
All study protocols were approved by the institu-
tional review board of the individual sites and for the
University of Rochester Clinical Trials Coordination
Center (CTCC) as outlined in the original BioFIND
manuscript.18 Moderate-to-advanced PD participants
with clinically typical features meeting basic and sup-
portive United Kingdom PD Society Brain Bank clinical
diagnostic criteria representing all H & Y stages and
HC subjects were enrolled at eight movement disorders
centers in the United States.18 Participants were selected
as a convenience series for those who volunteered for
the biomarker study without randomization or consec-
utive enrollment. Additional inclusion criteria for PD
patients included: expression of all three classic parkin-
sonian motor signs (bradykinesia, rigidity, and resting
tremor) by history or examination; disease duration
≥5 years and onset between ages 50 and 75 years; and
well-established response to dopaminergic agents
and/or amantadine. Subjects were excluded if they had:
features of atypical or secondary parkinsonian syn-
dromes; history of DBS or ablative brain surgery;
history of cancer (except basal or squamous cell skin
cancers) within 5 years preceding enrollment; autoim-
mune, liver, or hematological disorders; or conditions
precluding lumbar puncture. HCs were matched by sex
and age to PD subjects, were free of any known neuro-
logical disorders, and scored ≥26 on the Montreal
Cognitive Assessment (MoCA). Other exclusion criteria
for HCs were similar to those for PD subjects. Addition-
ally, HC subjects with any ﬁrst-degree family member
with PD were excluded to reduce the chance of enrolling
prodromal cases. Additional details regarding the cohort
are discussed in the original manuscript detailing the
BioFIND study.18
Evaluations
Clinical evaluation and biospecimen collection occurred
during two visits, one to establish the baseline (V1) and a
follow-up 2 weeks later (V2). For PD subjects, V1 was
performed during the on state (1–3 hours after the last
PD medication dose) and V2 was performed in the practi-
cally deﬁned off state (early morning before PD medica-
tions and approximately 12 hours after the last dose the
night before). During V1, blood for DNA and plasma
were collected and clinical assessments were made includ-
ing the International Parkinson and Movement Disorder
Society–sponsored revision of the UPDRS (MDS-UPDRS)
Parts I (nonmotor experiences of daily living), II (motor
experiences of daily living), III (motor examination), and
IV (motor complications) for PD subjects and only Part
III for HCs. During V2, blood for RNA and plasma,
CSF, and saliva (in a smaller subgroup) were collected,
and the MDS-UPDRS Part III was administered to PD
subjects. All subjects either fasted or consumed a low-fat
diet on the morning of V2 at the time of biospecimen col-
lection. CSF was immediately frozen in a –80

C freezer
and shipped to the biorepository on dry ice at a later
date.18 Data collected included demographics, family his-
tory of PD, medical/neurological histories, medications,
neurological exams, the MDS-UPDRS,19 MoCA,20 and
REM Behavior Sleep Disorder (RBD) Questionnaire21
and, for PD subjects, the Modiﬁed Schwab and England
Activities of Daily Living Scale.22
Synuclein Seeding Aggregation Assays
Two independent laboratories performed their respec-
tive assays on separate aliquots of CSF from the same
subjects. Both assays are based on the ability of patho-
logical α-synuclein oligomers to seed aggregation at the
expense of exogenously supplied monomeric α-synuclein
protein. Cyclic ampliﬁcation of protein misfolding (PMCA)
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adapted for α-synuclein oligomer formation was per-
formed by the Soto group,14 and the real-time quaking-
induced conversion (RT-QuIC) assay was performed by
the Green group.15 Both assays are recent adaptations of
the original PMCA method, ﬁrst developed for misfolded
prion proteins by the Soto lab23 and streamlined to use
ﬂuorescence detection by the lab of Byron Caughey.24
Differences include pH, shaking conditions, and source
of the recombinant α-synuclein protein as summarized
and compared to a recent publication of an α-synuclein
seeding aggregation assay (SAA) by the Caughey lab13 in
Supporting Information Table S1.
RT-QuIC
The RT-QuIC assay was performed as previously
described.15 The reaction buffer (RB) was composed of
100 mM of phosphate buffer (pH 8.2), 10 μM of Thio-
ﬂavin T (ThT), and 0.1 mg/mL of human recombinant
full-length (1–140 amino acids) α-synuclein (Lot No:
056M4113V; Sigma-Aldrich Ltd, Poole, UK). Each well
of a black 96-well clear bottom plate (Nalgene Nunc
International, Fisher Scientiﬁc Ltd, Loughborough, UK)
contained 98, 90, or 85 μL of RB (depending on vol-
ume of seed added) and 37  3 mg of 0.5-mm zirco-
nium/silica beads (Thistle Scientiﬁc Ltd, Glasgow, UK).
Reactions were seeded with 2 μL of working-strength
brain homogenate or 15 μL of undiluted CSF to a ﬁnal
reaction volume of 100 μL. Plates were sealed with a
plate sealer ﬁlm (Fisher Scientiﬁc Ltd, Loughborough,
UK) and incubated in a BMG Labtech FLUOStar
OPTIMA plate reader at 30C for 120 hours with inter-
mittent shaking cycles: double orbital with 1-minute
shake (200 rpm), 14-minute rest. ThT ﬂuorescence
measurements (450 nm excitation and 480 nm emis-
sion) were taken every 15 minutes. Each sample was
run in duplicate. A positive response was deﬁned as a
relative ﬂuorescence unit (RFU) value of >2 standard
deviations above the mean of the negative controls at
120 hours in both of the CSF duplicates. If only one of
two CSF sample replicates gave a positive response,
the RT-QuIC analysis of the CSF samples was repeated
in quadruplicate. A positive response in two or more
replicates was considered positive, otherwise the sample
was considered negative. Twenty four samples were
repeated because of discordant ﬁndings between techni-
cal duplicates on the ﬁrst run. Seventeen of these
showed concordance with clinical diagnosis on repeats.
Five were false positives and two were false negatives.
The ﬁnal ﬂuorescence value was the mean ﬂuorescence
value taken at 120 hours. The maximum ﬂuorescence
value was the highest mean ﬂuorescence value recorded
during the RT-QuIC analytical run of 120 hours. The
latency to reach 50% of the maximal ﬂuorescence value
was noted as T50. Examples of ThT curves are shown
in Supporting Information Figure S1. Intrasample precision
was 12.1%. This was calculated from repeated analysis of
individual aliquots of a CSF sample from a PD patient over
the 12-month study period.
PMCA
The PMCA assay was performed as previously
described.14 Brieﬂy, recombinant full-length α-synuclein
(containing a his-tag for puriﬁcation) at a concentration
of 1 mg/mL in 100 mM of PIPES (pH 6.5), 500 mM of
NaCl, were placed in opaque 96-well plates in the pres-
ence of 5 μM of ThT at a ﬁnal volume of 200 μL. For
each test, we added 40 μL of CSF from patients and con-
trols. Positive controls consisted of a well-documented
and previously screened healthy CSF sample spiked with
in vitro generated α-synuclein oligomeric seeds. Samples
were subjected to cyclic agitation (1 minute at 500 rpm
followed by 29 minutes without shaking) at 37C
for 400 hours. The increase in ThT ﬂuorescence was
monitored at excitation of 435 nm and emission of
485 nm, periodically, using a microplate spectroﬂuorom-
eter (Gemini-EM; Molecular Devices, Sunnywale, CA).
We set an experimentally deﬁned threshold of 1,000
ﬂuorescence units as the cut-off criteria for a “positive”
designation for each sample (samples below 1,000 were
classiﬁed as “negative”). Each sample was assayed in
triplicate, which showed a high degree of concordance.
One sample was deﬁned as uncertain positive, because
the maximum ﬂuorescence was higher than 1,000 in only
two of the three replicates. Three samples were deﬁned
as uncertain negative, because two of the three replicates
did not show aggregation. These results were concordant
with the clinical diagnosis and RT-QuIC results.
The PMCA assays for α-synuclein showed speciﬁcity
toward α-synuclein seed compared to β-amyloid (1-42)
and tau proteins.14 In addition, immunodepletion of
α-synuclein from the CSF signiﬁcantly delayed time
needed to reach 50% of maximum ﬂuorescence (T50),
indicating removal of the majority of the seeds. When
the same samples were used for assay at a later time
and when measured after one versus two freeze-thaw
cycles, a good reproducibility of data was demonstrated
previously. Varying seed concentrations resulted in cor-
responding changes in T50.
14 Dilution curve of BioFIND
reference pool CSF also showed corresponding changes
in T50 (Soto, unpublished).
Statistical Analysis
Differences between cases and controls were com-
pared using percent and frequency for categorical data
and median and range for continuous data. Categorical
data were assessed using chi-square or Fisher’s exact
test, where appropriate, and differences in continuous
data was assessed using Wilcoxon rank sum. Sensitiv-
ity, speciﬁcity, negative predictive value (NPV), and
positive predictive value (PPV) were calculated for
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comparisons between biomarker results and clinical
diagnosis. Correlations were calculated for biomarker
results between the two techniques as well as between
biomarker results and clinical characteristics. Logistic
regression was used to generate receiver operating charac-
teristic (ROC) curves to assess the relationship between
biomarker results and clinical diagnosis of PD. A two-
tailed alpha of 0.05 was used.
Data Availability Statement
Individual de-identiﬁed participant data consisting of
clinical phenotypes, demographics, and assay data are
available online (http://bioﬁnd.loni.usc.edu/). The data
are publically available upon registration by the Michael
J. Fox Foundation for Parkinson’s Research. The study
protocol is available (https://www.michaeljfox.org/page.
html?bioﬁnd-clinical-study). The statistical analysis is avail-
able upon request from the authors.
Results
A total of 105 PD subjects and 79 HC subjects with
results from both assays were included in the analysis.
Subject demographics are shown in Table 1. Whereas
both assays were similar (Supporting Information
Table S1), the PMCA assay gave a range of maximum
ﬂuorescence values, whereas the RT-QuIC assay yielded
either positive or negative signal based on the endpoint
ﬂuorescence level (Fig. 1A). Overall, 92% of subjects
showed concordant results across both assays. Eleven
subjects were positive by RT-QuIC, but negative by
PMCA, and 4 subjects were positive by PMCA, but neg-
ative by RT-QuIC (Fig. 1A). Time needed to reach T50
varied among the positive samples in both assays, and all
the samples with negative results based on the maximum
ﬂuorescence had no measurable T50 values. Though the
maximum ﬂuorescence and T50 values for the PMCA
assay were continuous, they showed only moderate cor-
relation (R2 = 0.5569 for PMCA; P < 0.0001). T50 values
in PD subjects from two assays were only weakly corre-
lated (R2 = 0.4748; P < 0.0001; Fig. 1B).
Overall, both assays exhibited high accuracy for clini-
cal diagnosis of PD. Areas under the curve (AUCs) of
ROC curves were 0.94 when considering only the sam-
ples with concordant results between both assays. Sepa-
rately, AUCs for the PMCA and RT-QuIC assays were
0.93 and 0.89, respectively (Table 2). Sensitivity, speci-
ﬁcity, PPV, and NPV and AUC from ROC analysis are
shown in Table 2.
Clinical characteristics of false-positive and -negative
subjects, including age at enrollment, UPDRS total and
UPDRS part III scores, H & Y stage, and RBD score
were not signiﬁcantly different from true-negative and
-positive subjects, respectively (Fig. 2). This was also the
case for CSF α-synuclein, β-amyloid (1-42), total tau
(t-tau), and tau phosphorylated at threonine 181 (p-tau)
levels (Fig. 2). Although predictive values of the SAAs
TABLE 1. Demographic characteristics in the BIOFIND samples
Total (N = 184) Cases (N = 105) Controls (N = 79)
N (%) N (%) N (%) P Value
Male, % 101 (54.9) 63 (62.4) 38 (37.6) 0.108
White, % 171 (92.3) 99 (94.3) 72 (91.1) 0.410
Median (range) Median (range) Median (range)
Age at enrollment 66 (55–84) 68 (55–82) 65 (53–84) 0.997
MoCA 28 (19–30) 27 (19–30) 28 (26–30) 0.0003
RBD score 3 (0–13) 5 (0–13) 2 (0–8) 0.0001
RBD >5, % 50 (27.2%) 47 (44.8%) 3 (3.8%) 0.0001
TD, % — 51.4% — —
PIGD, % — 37.1% — —
α-Synuclein 1,469.5 (378–3,852.8) 1,421.4 (378–3,449.3) 1,590.7 (86.3–3,852.8) 0.009
β-Amyloid (1-42) 323.1 (11.4–500.7) 289 (123.6–468.3) 354.9 (11.4–500.7) 0.003
t-tau 35.3 (1.0–172.4) 33.6 (1.0–98.9) 36.1 (1.0–172.4) 0.115
p-tau 13.9 (4.3–127.9) 12.6 (4.3–76.6) 14.6 (5.4–127.9) 0.0542
Age at PD onset — 61 (51–76) — —
Duration of PD since onset — 8 (4–17) — —
LEDD — 680 (100–2,045.5) — —
UPDRS part I — 9 (0–27) — —
UPDRS part II — 11 (0–34) — —
UPDRS part III off 12.5 (0–66) 26 (7–66) 1 (0–10) 0.0001
UPDRS part IV — 4 (0–12) — —
UPDRS total on — 46 (12–127) — —
UPDRS total off — 59 (22–133) — —
H & Y stage — 2 (1–4) — —
Abbreviations: TD, tremor-dominant subtype; PIGD, postural instability and gait disorders subtype; LEDD, levodopa-equivalent daily dose.
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were high for the diagnosis of PD, the primary assay
parameters of maximum ﬂuorescence and T50 did not
correlate with any clinical parameter, including disease
duration, age, sex, or UPDRS scores (Supporting Infor-
mation Table S2; Fig. 3). We also tested whether maxi-
mum ﬂuorescence or T50 values from the α-synuclein
SAAs correlated with total CSF α-synuclein, β-amyloid,
t-tau, and p-tau levels and did not see any signiﬁcant
relationships (Supporting Information Table S2).
Though the BioFIND cohort was purposely designed
to reduce the chances of including genetic forms of PD,
common glucocerebrosidase (GBA) and leucine repeat-
rich kinase 2 (LRRK2) variants were present in a few
PD patients and HCs without PD.25 Based on published
studies, we hypothesized that GBA mutations may
increase α-synuclein pathology whereas some LRRK2
mutations may lack α-synuclein pathology.26,27 We had
7 PD and 2 HC subjects with pathogenic GBA variants,
and 1 PD and 1 HC subject with the LRRK2 G2019S
mutation. However, the assay results from these genetic
variants of PD did not show any differences from sub-
jects without established abnormal genetic variants and
were concordant with their clinical diagnosis.
Discussion
Development of new biomarkers assays often face sig-
niﬁcant challenges in replicability in additional patient
cohorts. Because of the complexity of obtaining and
assaying human samples, variability may arise in many
areas, including from differences in patient enrollment,
biospecimen collection and processing, and assay execu-
tion. Thus, independent replication and cross-validation
of assays is a critical step that is often lacking in the liter-
ature. Therefore, we utilized the BioFIND cohort, a stan-
dardized benchmark cohort of PD patients, for blinded
assay validation of two α-synuclein aggregation assays
based on the sample principle. These assays use CSF to
seed the aggregation of monomeric α-synuclein protein
and are among the most promising biomarkers for PD
diagnosis. Our results validate the preliminary studies
and show robust power to conﬁrm PD diagnosis from
the same CSF samples at the individual level.13-15 This is
contrasted by the consistent ﬁnding that total α-synuclein
protein levels are lower in CSF from PD patients com-
pared to HCs at the population level, with signiﬁcant
overlap between the two groups.17,28,29
Although the concordance rate was high between
the two assays (92%; Fig. 1), we did not ﬁnd any
systematic explanation for the discrepant ﬁndings. This
included comparison of the borderline or nonunani-
mous results between assays, clinical and biochemical
characteristics of patients, and correlation of assay
parameters (i.e., samples with longer T50 times in one
FIG. 1. Distribution of assay parameters in BioFIND subjects. Maximum ﬂuorescence values were used to designate positive or negative aggregation
results. The PMCA assay yielded graded maximum ﬂuorescence whereas the RT-QuIC values were binary. (A) Maximum ﬂuorescence values from the
PMCA assay were plotted against positive or negative designations in the RT-QuIC assay. The dotted line designates the cut-off threshold for a posi-
tive result by PMCA (1,000 RFUs). (B) T50 of the PMCA assay was plotted against the RT-QuIC assay. Green boxes = healthy control subjects; red dia-
monds = PD subjects; dotted line = linear regression line (R2 = 0.47; P < 0.0001).
TABLE 2. Predictability of assays for PD diagnosis
Only Assay
Concordant
Subjects Included PMCA RT-QuIC
Sensitivity 97.1% (92.9–99.1) 95.2% (90.6–98.0) 96.2% (91.4–98.7)
Speciﬁcity 92.5% (86.2–95.7) 89.9% (83.8–93.5) 82.3% (76.0–85.6)
PPV 95.2% (91.1–97.2) 92.6% (88.1–95.2) 87.8% (83.5–90.1)
NPV 95.4% (88.9–98.6) 93.4% (87.1–97.2) 94.2% (87.0–98.0)
AUC 0.9480 0.9256 0.8923
Sensitivity, speciﬁcity, PPV, NPV, and AUC of the ROC analysis. Values in
parentheses indicate 95% conﬁdence intervals. Of 105 PD and 79 HC sub-
jects, the assay results were concordant in 102 PD and 67 HC subjects.
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FIG. 2. Comparison of clinical characteristics and CSF analyte values of subjects with assay results discordant with clinical diagnosis. Values from
false-positive and -negative α-synuclein seeding assay results common to both assays, or unique to each assay, were compared to the true-negative
and -positive subjects, respectively. There were no differences for (A) age of enrollment, (B) UPDRS total score, (C) CSF α-synuclein levels, (D) CSF
β-amyloid (1-42) levels, (E) RBD score, (F) UPDRS part III score, (G) CSF tau levels, and (H) phospho-tau protein levels.
FIG. 3. Correlation of T50 values to disease characteristics for PD patients. T50 values of the PMCA (A–C) and RT-QuIC (D–F) assays were plotted
against (A and D) H & Y stage, (B and E) total UPDRS part III, and (C and F) UPDRS total scores for PD patients with positive assay results. For the
PMCA assay: n = 100, (A) R2 = 0.0099, P = 0.3235, (B) R2 = 0.0013, P = 0.7202, and (C) R2 = 0.0004, P = 0.8458. For the RT-QuIC assay: n = 101,
(D) R2 = 0.0093, P = 0.3365, (E) R2 = 0.0039, P = 0.5338, and (F) R2 = 0.0100, P = 0.3204.
6 Movement Disorders, 2019
K A N G E T A L
assay lacking aggregation in the other). Thus, discor-
dant results may be attributed to the slight differences
in the conditions, reagents, and procedures for each
assay (Supporting Information Table S1) and may
improve with further optimization.
In both assays, maximum ﬂuorescence values were used
to designate a “positive” result. The RT-QuIC assay
was optimized for maximum sensitivity for PD detec-
tion, yielding nearly all-or-none ﬂuorescence levels.15
The PMCA assay produced a range of maximum ﬂuores-
cence values and used an experimentally derived cut-off
value (1,000 RFUs in this study) for characterization
(Fig. 1A). These differences resulted in higher sensitivity
of RT-QuIC (96.2% vs. 95.2%) and higher speciﬁcity of
PMCA (89.9% vs. 82.3%; Table 2). When only consid-
ering samples with concordant results from both assays,
speciﬁcity of the assay improved to 92.5% and sensitiv-
ity increased to 97.1%, suggesting that using both assays
together would further improve diagnostic performance.
These α-synuclein SAAs have the highest diagnostic
accuracy for PD biomarkers reported in the literature.
Head-to-head comparison with DATSCAN in the same
cohort will be useful in determining whether α-synuclein
SAAs can be substituted for expensive imaging for PD
diagnosis.
In this study, both assays yielded a varying range of
T50 values (Fig. 1B), suggesting that this parameter may
reﬂect the amount of α-synuclein seeding species present
in the assay. In a previous study, T50 values of the
PMCA assay correlated to the amount of α-synuclein olig-
omer seed spiked into control CSF and the H& Y stage in
patient CFS samples.14 However, T50 values from either
assay did not correlate to any clinical parameter in the pre-
sent study (Supporting Information Table S2; Fig. 3).
Given that the T50 values showed only weak correlation
between assays, the current assay conditions may not
reﬂect quantitative aspects of the seeding capacity of CSF
samples (Fig. 1B), which may also be true for the maxi-
mum ﬂuorescence values. A similar assay published
recently13 used nondisease K23Q mutant α-synuclein pro-
tein (Supporting Information Table S1) with a shortened
assay time and demonstrated high sensitivity and speciﬁc-
ity, though only a small number of CSF samples were
assayed.13 Whether our results indicate that the level of
pathogenic α-synuclein species capable of seeding aggrega-
tion in the CSF do not change with disease stage or reﬂect
limitations of the assays as implemented are currently
being addressed. The BioFIND cohort contains patients
with H & Y stage 1 to 4 with a mean of 2.1 and lacks de
novo and H & Y stage 5 patients. Further studies with a
wider spectrum of PD stages, including prodromal stages,
and a longitudinal cohort will be important to address
whether levels of pathological forms of α-synuclein in CSF
are changed with disease severity and progression.
Importantly, these assays probe a process that may be
central to PD pathogenesis and strongly support that
misfolded α-synuclein protein present in CSF of PD patients
can seed the aggregation of monomeric α-synuclein protein
by propagating an aberrant protein conformation in a
prion-like fashion. Although data collection from the
BioFIND cohort ended with the ﬁnal visit, precluding
the possibility of obtaining pathology information, a pre-
vious study using the RT-QuIC assay included 2 PD,
11 dementia with Lewy bodies, 30 Alzheimer’s disease,
and 20 HC subjects with pathological conﬁrmation of
diagnosis and showed high sensitivity and speciﬁcity
for Lewy body diseases.15 Though CSF from atypical
parkinsonism cases also seed aggregation in these
assays,13-15 the physical nature of these aggregates may
differ based on the disease. For instance, aggregates
induced by α-synuclein obtained from glial cytoplasmic
inclusions in MSA have different properties than those
seeded from Lewy body (LB)-derived α-synuclein.30
We are currently developing methods to identify the
types of aggregates formed in the SAAs, which may be
useful to differentiate PD from atypical parkinsonism.
Importantly, CSF from tauopathies, such as supranuclear
palsy, did not seed α-synuclein aggregation in either
assay.14,15 Of note, there are rare cases of PD that lack
LB pathology, including the R1441 and G2019S LRRK2
mutations, in which the role of synucleinopathy in dis-
ease pathogenesis is questioned.26,27,31 There were 2 cases
of G2019S LRRK2 mutation in the present BioFIND
cohort: 1 PD and HC subject. Both α-synuclein SAAs
showed results concordant with the clinical diagnoses.
Though CSF samples were obtained after overnight
withdrawal of medication, all PD patients in the Bio-
FIND cohort were treated with dopaminergic drugs
and/or amantadine for symptomatic control. Although
these drugs have been shown not to affect total
α-synuclein levels in plasma and CSF,32,33 we cannot
rule out the effect of dopaminergic medication on
α-synuclein aggregation. The previous studies using
these SAAs did not specify medication use in their PD
subjects.13-15 Inclusion of de novo PD subjects, who
are drug naïve, such as those included in the PPMI
cohort, would address the effect of dopaminergic
drugs on seeding ability of CSF α-synuclein.
Overall, our results show robust power of α-synuclein
SAAs to predict clinical diagnosis in a typical moderate
PD cohort by independently cross-validating two differ-
ent assay platforms using the same CSF samples. Given
that these assays report on a process central to disease
pathogenesis, they have the potential to be a surrogate
for the presence of α-synuclein pathology and should be
tested with larger cohorts of patients with pathological
conﬁrmation of PD compared to other pathologies.
Such predictive power will increase the rigor for PD
diagnosis and improve subject selection for therapeu-
tic trials. Additionally, these assays may provide the
opportunity to directly evaluate target engagement and
efﬁcacy of therapeutic modalities that target α-synuclein
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levels or aggregation. Whether SAAs can aid in earlier
diagnosis by detecting pathogenic processes during pro-
dromal phases before clinical manifestation remains to
be systematically studied. CSF from the same 5 HC sub-
jects was classiﬁed positive by both assays. Although
informal follow-up of 3 of these patients did not show
conversion to a PD phenotype, long-term follow-up is
necessary to determine whether these “false positives”
were actually prodromal cases. Likewise, whether these
assays have utility in tracking disease progression and
severity will require further development. In addition, the
utility of these assays needs to be further evaluated in a
wider range of cross-sectional and longitudinal cohorts.
Given the high concordance of the results obtained
by the PMCA and RT-QuIC assays, the similarity on
the principles and methodology, it would be advisable
to unify the name of these assays to avoid confusion in
the literature. We propose to use the term “seeding
aggregation assay (SAA)” to refer to these tests in order
to highlight the basic principle behind them. Based on
their high predictive power, these α-synuclein SAAs
tested in our study have the potential to revolutionize
PD diagnosis for clinical practice and clinical trials.
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